Clinical effects of liraglutide on diabetes control in Japanese type 2 diabetes mellitus patients

Aims Our goal was to evaluate liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in monotherapy and combination therapy for Japanese type 2 diabetes patients. Materials and methods Patients with type 2 diabetes (111 men, 83 women; mean age 57.6 ± 12.6 years) were treated with liraglutide and divided into liraglutide monotherapy ( n = 147 patients, group A) and liraglutide–sulfonylurea (SU) combination therapy ( n = 47, group B) groups. Changes in clinical parameters after liraglutide administration were evaluated. Results In both groups, significant decreases in glycosylated hemoglobin (HbA1c) were seen after 12 (group A, 7.01 ± 1.38 vs. 7.72 ± 1.57 %, p